We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$861M
Cap. Flow %
17.92%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
2 Financials 0.49%
3 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
76
MoonLake Immunotherapeutics
MLTX
$1.56B
$4.44M 0.09%
400,000
– –
REUN
77
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$3.99M 0.08%
595,200
-45,800
-7% -$381K
OBIO icon
78
Orchestra BioMed
OBIO
$228M
$3.96M 0.08%
400,000
– –
LENZ
79
LENZ Therapeutics
LENZ
$179M
$3.62M 0.08%
101,429
– –
ONCS
80
DELISTED
OncoSec Medical Incorporated
ONCS
$3.39M 0.07%
133,864
– –
OTIC
81
DELISTED
Otonomy, Inc.
OTIC
$3.24M 0.07%
+1,349,905
New +$2.87M
WGS icon
82
GeneDx Holdings
WGS
$1.89B
$2.92M 0.06%
28,788
– –
CMPX icon
83
Compass Therapeutics
CMPX
$349M
$2.74M 0.06%
2,000,000
– –
GRTS
84
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.31M 0.05%
560,000
-3,810,000
-87% -$20.2M
SNCE
85
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.3M 0.05%
21,500
+1,800
+9% +$282K
SCYX icon
86
SCYNEXIS
SCYX
$37.4M
$2.13M 0.04%
68,005
-211,905
-76% -$8.11M
PROK icon
87
ProKidney
PROK
$316M
$1.98M 0.04%
200,000
– –
AKLI
88
DELISTED
Akili Inc
AKLI
$1.98M 0.04%
200,000
– –
DNAB
89
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.95M 0.04%
200,000
– –
DNAD
90
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.95M 0.04%
200,000
– –
NUVB.WS
91
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$76K ﹤0.01%
99,999
– –
MSACW
92
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$25K ﹤0.01%
57,770
– –
ACAD icon
93
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-300,000
Closed -$7M
ALNY icon
94
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-370,000
Closed -$62.7M
AMN icon
95
AMN Healthcare
AMN
$1.35B
– –
-280,100
Closed -$34.3M
DH icon
96
Definitive Healthcare
DH
$77M
– –
-250,000
Closed -$6.83M
GLUE icon
97
Monte Rosa Therapeutics
GLUE
$1.82B
– –
-300,000
Closed -$6.13M
HOLX
98
DELISTED
Hologic
HOLX
– –
-1,064,000
Closed -$81.5M
HOWL icon
99
Werewolf Therapeutics
HOWL
$22.4M
– –
-485,000
Closed -$5.78M
KYMR icon
100
Kymera Therapeutics
KYMR
$8.66B
– –
-670,000
Closed -$42.5M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $861M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.